# Continuous Motor Monitoring: Implementation and Value

Webinar Will Begin at 12:00 PM EDT

### G R E A T L A K E S NEUROTECHNOLOGIES


# Outline

- Standard and technology-based assessment of motor symptoms
- Kinesia HomeView overview
- Motion sensor rating tremor in a laboratory setting during activities of daily living
- Continuous motion sensor rating of tremor at home




### Standard Assessment of Involuntary Motor Symptoms

#### **Clinician Ratings**



**Patient Diaries** 




- Limited resolution
- Limited reliability
- Placebo effects

- Compliance
- Recall bias
- Poor self-assessment



### **Technology-based Assessment**













O 1998 DOLE Threaded Publick Derman

### **Clinical Validation - Tremor**










# **Clinical Validation - Bradykinesia**



Objective Quantification


Kinematic features are highly correlated to clinician MBRS scores

#### Published

Heldman, DA; Giuffrida, JP; Chen, R; Payne, M; Mazzella, F; Duker, AP; Sahay, A; Kim, SJ; Revilla, FJ; Espay, AJ. The Modified Bradykinesia Rating Scale for Parkinson's disease: Reliability and Comparison with Kinematic Measures. *Movement Disorders*. 2011.



# **Clinical Validation - Dyskinesia**



Published



Mera, TO, Burack, MA, and Giuffrida, JP. "Quantitative Assessment of Levodopa Induced Dyskinesia Using Automated Motion Sensing Technology", IEEE-EMBS Proceedings 2012.



## **Capturing Fluctuations**

CD

Time	Rest Tremor	Postural Tremor	Finger Taps Speed	Finger Taps Amplitude	Finger Taps Rhythm	Oyskinesia	
7:01 AM	4.0	3.5	2.5	2.4	2.2	0.0	
7:02 AM		SIN	EMET	(100	mg)		
7:32 AM	3.4	3.3	1.7	1.4	1.0	0.0	
8:01 AM	3.0	3.0	1.8	1.8	1.2	0.0	
8:34 AM	2.9	2.8	1.3	1.2	1.0	0.0	
9:00 AM	2.8	2.4	1.2	1.1	1.2	0.0	
9:23 AM	2.8	2.6	1.0	1.0	1.0	0.0	
10:00 AM	2.6	2.8	1.0	1.0	1.0	0.0	
10:33 AM	3.2	3.3	1.5	1.9	1.5	0.0	
11:01 AM	3.5	3.5	2.3	2.2	2.0	0.0	
11:30 AM	3.7	3.8	2.0	2.0	1.8	0.0	



Time	Rest Tremor	Postural Tremor	Finger Taps Speed	Finger Taps Amplitude	Finger Taps Rhythm	Dyskinesia
7:01 AM	4.0	3.5	2.5	2.4	2.2	0.0
7:02 AM			EMET			
7:32 AM	3.4	3.3	1.7	1.4	1.0	0.0
8:01 AM	3.0	3.0	1.8	1.8	1.2	0.0
8:34 AM	2.9	2.8	1.3	1.2	1.0	0.0
9:00 AM	2.8	2.4	1.2	1.1	1.2	0.0
9:23 AM	2.8	2.6	1.0	1.0	1.0	0.0
10:00 AM	2.6	2.8	1.0	1.0	1.0	0.0
10:33 AM	3.2	3.3	1.5	1.9	1.5	0.0
11:01 AM	3.5	3.5	2.3	2.2	2.0	0.0
11:30 AM	3.7	3.8	2.0	2.0	1.8	0.0
12:00 PM		SIN	EMET	(100	mg)	
12:01 PM	3.3	3.8	2.6	2.7	2.0	0.0
12:32 PM	3.2	3.4	1.8	1.9	2.0	0.0
1:08 PM	2.6	3.1	2.0	1.4	1.8	0.0
1:28 PM	2.6	2.9	1.5	1.2	1.7	0.0
2:00 PM	2.7	2.7	1.3	1.0	1.5	0.0
2:32 PM	2.9	2.6	1.0	1.2	1.7	0.0
3:00 PM	3.0	2.9	1.1	1.5	1.3	0.0
3:29 PM	3.3	3.1	1.4	1.7	1.7	0.0
4:02 PM	3.8	3.6	1.6	1.8	1.8	0.0
4:30 PM	3.9	3.8	1.9	1.9	2.0	0.0
5:01 PM	3.9	3.9	2.5	2.4	2.0	0.0
5:15 PM		SIN	EMET	(100	mg)	
5:29 PM	3.5	3.6	2.1	2.2	2.0	0.0
6:02 PM	3.3	3.5	2.0	2.1	1.6	0.0
6:30 PM	3.0	2.9	1.9	2.0	1.5	0.0
7:00 PM	2.8	2.5	1.5	1.8	1.3	0.0
7:33 PM	2.6	2.6	1.2	1.5	1.1	0.0
8:04 PM	2.6	2.6	1.0	1.4	0.9	0.0
8:30 PM	2.9	2.8	1.2	1.5	1.1	0.0
9:02 PM	3.3	3.2	1.3	1.6	1.4	0.0
9:33 PM	3.5	3.6	1.6	1.8	1.8	0.0
10:00 PM	3.8	3.9	2.0	1.9	2.1	0.0
Mean	3.2	3.2	1.6	1.7	1.6	0.0
Fluctuation	0.4	0.5	0.5	0.4	0.4	0.0


	Time	Rest Tremor	Postural Tremor	Finger Taps Speed	Finger Taps Amplitude	Finger Taps Rhythm	Dyskinesia	
	6:55 AM	3.9	3.4	2.6	2.5	2.3	0.0	
	6:57 AM			EMET				
	7:28 AM	2.5	3.0	1.7	1.4	1.0	0.0	
	7:59 AM	0.5	1.9	1.8	1.5	1.2	1.3	
	8:30 AM	0.3	0.9	0.3	0.5	1.0	2.9	
	9:05 AM	0.1	0.5	0.2	0.2	1.2	3.5	
	9:33 AM	0.3	0.4	0.0	0.0	1.0	3.8	
	10:02 AM	0.5	0.1	0.5	0.3	1.0	3.7	
	10:31 AM	1.5	2.0	1.0	0.5	1.5	2.9	
	10:58 AM	3.0	3.1	2.3	2.2	2.0	0.0	
	11:35 AM			2.0				
	11:50 PM	SINEMET (300mg)						
Increase dose by 200mg,	11:56 PM	1.1	2.7	2.3	2.2	2.0	0.0	
	12:30 PM	0.2	2.0	1.8	1.9	2.0	3.0	
	1:04 PM	0.1	1.4	2.0	1.4	1.8	3.3	
	1:38 PM	0.0	1.1	0.8	0.9	1.7	3.5	
Dose interval	2:02 PM	0.0	1.0	0.6	1.0	1.5	3.6	
unchanged	2:30 PM	0.2	1.0	1.0	1.2	1.7	2.4	
unonungeu	3:07 PM	0.4	0.7	1.1	1.5	1.3	1.1	
	3:33 PM 4:03 PM	0.5	1.3	1.4	1.7	1.7	0.0	
	4:03 PM 4:28 PM	2.6	1.5	1.6	1.8	1.8	0.0	
	4:28 PM	3.5	2.0	1.9	1.9	2.0	0.0	
	5:05 PM	0.0		EMET			0.0	
	5:39 PM	3.5	2.2	2.1	2.2	2.0	0.0	
	6:03 PM	2.3	2.0	2.0	2.1	1.6	0.0	
	6:29 PM	1.7	1.3	1.9	2.0	1.5	0.5	
	7:05 PM	0.8	1.1	1.5	1.8	1.3	1.0	
	7:36 PM	0.6	0.8	1.2	1.5	1.1	2.3	
	8:01 PM	0.3	0.6	1.0	1.4	0.9	3.8	
	8:28 PM	0.2	1.0	1.2	1.5	1.1	3.7	
	9:00 PM	0.3	1.1	1.3	1.6	1.4	1.3	
	9:34 PM	0.3	2.0	1.6	1.8	1.8	0.5	
	9:59 PM	2.8	2.3	2.0	1.9	2.1	0.0	
,	Mean Fluctuation	1.3 1.3	1.6 0.9	1.4 0.7	1.5 0.6	1.6 0.4	1.6 1.5	

Time	Rest Tremor	Postural Tremor	Finger Taps Speed	Finger Taps Amplitude	Finger Taps Rhythm	Dyskinesia
7:00 AM	3.5	3.2	2.7	2.5	2.4	0.0
7:01 AM			EMET		mg)	
7:31 AM	2.0	2.1	1.9	2.1	2.2	0.0
8:00 AM	0.6	0.7	0.3	0.5	1.0	0.0
8:33 AM	0.3	0.5	0.2	0.2	1.2	0.0
8:59 AM	0.2	0.2	0.0	0.0	1.0	0.0
9:22 AM	0.2	0.0	0.5	0.3	1.0	0.0
9:59 AM	1.1	1.5	1.0	0.5	1.5	0.0
10:32 AM			EMET			
11:00 AM	1.2	1.3	1.5	1.4	1.5	0.0
11:29 AM	0.3	0.3	0.5	0.6	2.1	0.0
11:59 PM	0.2	0.2	0.3	0.3	1.0	0.0
12:00 PM	0.1	0.0	0.4	0.1	2.3	0.0
12:31 PM	0.2	0.6	0.6	0.1	2.1	0.0
1:07 PM	1.2	1.6	1.7	1.6	1.7	0.0
1:27 PM		International Property in which the Party name	EMET	and of the local division in the	Station of Concession, Name	0.0
1:59 PM	1.0	0.8	1.0	0.9	1.0	0.0
2:31 PM	0.3	0.7	0.3	0.8	0.9	0.0
2:59 PM	0.2	0.5	0.2	0.5	0.9	0.0
3:28 PM	0.0	0.3	0.2	0.8	0.9	0.0
4:01 PM	0.5	0.8	0.9	1.6	1.7	0.0
4:29 PM	1.3	1.7	1.6	2.1	2.1	0.0
5:00 PM 5:14 PM	10		EMET 1.0	the second second	Support of the local division of the local d	0.0
5:28 PM	1.0	1.5 0.6	0.3	0.9	1.0	0.0
6:01 PM	0.3	0.0	0.3	0.5	2.4	0.0
6:29 PM	0.0	0.0	0.2	0.8	1.7	0.0
6:59 PM	0.5	0.2	0.2	1.6	1.2	0.0
7:32 PM	1.3	0.9	1.6	2.1	1.0	0.0
8:03 PM	1.5		EMET			0.0
8:29 PM	0.8	0.6	0.5	0.7	0.5	0.0
9:01 PM	0.0	0.2	0.2	1.1	0.9	0.0
9:32 PM	0.0	0.1	0.9	1.6	1.3	0.0
9:55 PM	0.5	0.6	1.9	2.0	1.9	0.0
Mean Fluctuation	0.7 0.7	0.8 0.7	0.8	1.0 0.7	1.5 0.5	0.0

Decrease dose by 100mg, Decrease dose

interval by 2 hours





Reduce Patient Burden + Improve Compliance



#### **Challenges in Continuous Tremor Monitoring**



Movement Episodes of Variable Duration

Discerning Regular Activities from Symptoms

### **Tremor Assessment During Simulated ADLs**


- 10 subjects with essential tremor wore motion sensors on the index finger in a laboratory
- Performed standardized tasks from the WHIGET tremor rating scale and nonstandardized simulated ADL tasks
- Tremor rated by movement disorder specialists and by motion sensor system




Heldman, DA; Jankovic, J; Vaillancourt, DE; Prodoehl, J; Elble, RK; Giuffrida, JP. Essential Tremor Quantification During Activities of Daily Living. *Parkinsonism and Related Disorders*. 2011.

### **Tremor Assessment During Simulated ADLs**

 Mathematical models produced ADL task ratings that correlated well with recent clinician ratings of standardized tasks








### **Continuous Tremor Assessment at Home**

- 20 ET subjects wore the motion sensor for up to 10 hours per day on 2 separate days
- Completed standardized motion sensor tremor assessments at one-hour intervals to serve as checkpoints








Rest

Postural



**Kinetic** 

### **Continuous Tremor Assessment at Home**




- Mathematical model uses processed motion sensor data to rate tremor amplitude severity every 12 seconds
- 5-minute sliding window used to filter the continuous scores



### **Continuous Tremor Assessment at Home**

- Distribution of tremor scores is a quick tool for evaluating effectiveness of changes to therapy
- System can also be leveraged to monitor medication doseresponse





# Conclusions

- Tremor can be accurately rated during activities of daily living performed in a laboratory setting
- Tremor can be rated on a continuous basis without prior knowledge of activity using a single finger-worn sensor in patients' homes
- Dyskinesia rating is in our pipeline and future work will evaluate continuous dyskinesia monitoring with an optimized sensor suite



### Acknowledgements

### RUSH UNIVERSITY Christopher Goetz, MD Sheila Eichenseer, MD

# **BCM**°

Baylor College of Medicine

Joseph Jankovic, MD Olga Waln, MD Christine Hunter, RN

**UF FLORIDA** David Vaillancourt, PhD Dustin Heldman, PhD Joseph Giuffrida, PhD Thomas Mera, MS



National Institute on Aging ■ ◆ ¥ ≇

#### NIH/NIA 2R44AG034708-02A1

G R E A T L A K E S NEUROTECHNOLOGIES



Please contact: Christopher Pulliam, PhD Senior Biomedical Engineering Researcher cpulliam@glneurotech.com

